Illumina

Global Microarray Industry Research 2023-2024 & 2033: Rising Numbers of Genomics Projects, Developing Focus on Automation and Artificial Intelligence Integration - ResearchAndMarkets.com

Retrieved on: 
木曜日, 5月 16, 2024
Health, Genetics, Genomics, Gene expression profiling, Proteomics, DNA, Competitive landscape, Gene expression, Limited partnership, Prevalence, Conditional sentence, Region, Disease, Drug development, Microarray, Growth, Research, Cancer, Drug discovery, Medicine, Gene, Genetic variation, Merck, Software, Thermo Fisher Scientific, Illumina, Vaccine

This growth can be attributed to rising numbers of genomics projects fuelling the growth of microarray analysis market, use of microarray technology in drug screening, increasing adoption of microarray technology in cancer screening.

Key Points: 
  • This growth can be attributed to rising numbers of genomics projects fuelling the growth of microarray analysis market, use of microarray technology in drug screening, increasing adoption of microarray technology in cancer screening.
  • The global microarray analysis market has a significant impact on the biomedical industry, particularly in genomics and personalized medicine.
  • The global microarray analysis market continues to drive transformative advancements across industries, with far-reaching implications for human health, and environmental sustainability.
  • DNA microarrays are poised to maintain their dominance in the global microarray analysis market due to their critical role in genomics research.

GRAIL to Host Capital Markets Day

Retrieved on: 
月曜日, 5月 13, 2024
Oncology, Medical Devices, Health, Genetics, Health Technology, Biotechnology, Patient, Illumina, Methylation, Liver, Capital market, Growth, Cancer, Outline, Webcast, MSHS, Management

GRAIL, LLC., a healthcare company whose mission is to detect cancer early when it can be cured, today will host a virtual Capital Markets Day.

Key Points: 
  • GRAIL, LLC., a healthcare company whose mission is to detect cancer early when it can be cured, today will host a virtual Capital Markets Day.
  • Illumina has communicated its goal to finalize divestment terms for GRAIL by the end of the second quarter of 2024.
  • At GRAIL, we are advancing our mission to detect cancer early, when it can be cured, on behalf of patients every day,” said Bob Ragusa, CEO at GRAIL.
  • GRAIL leadership will outline the Company’s core strategy and catalysts for long-term growth, including:
    The live webcast will begin at 10:00 a.m.

Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK

Retrieved on: 
月曜日, 5月 13, 2024
NGS, Oxford Nanopore Technologies, Diabetes, Infection, Genomics, Illumina, University, Alzheimer's disease, Collection, Multiomics, Research, Personalized medicine

BURLINGTON, Mass., May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.

Key Points: 
  • BURLINGTON, Mass., May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.
  • The new laboratory brings Azenta closer to UK-based researchers, providing advanced next-generation sequencing (NGS) platforms and a local team of top-tier scientists from Oxford.
  • "We're thrilled to open our Oxford laboratory, which allows us to bring state-of-the-art NGS technology to UK researchers," said Dr Ginger Zhou, President of Azenta's Multiomics business unit.
  • "This new facility not only strengthens our global footprint but also offers researchers access to local experts and cutting-edge resources.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
水曜日, 4月 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
水曜日, 4月 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.

Global Proteomic Biomarker Analytics Market Analysis Report 2024 with Executive & Consultant Guides; Including Customized Forecasting and Analysis - ResearchAndMarkets.com

Retrieved on: 
金曜日, 3月 29, 2024
Health, Biotechnology, Illumina, Assay, Place, Proteomics, Genomics, Research, Cancer, Application

The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Where genomics couldn't find all the answers proteomics is stepping up to the plate.
  • Proteomic Biomarker Analytics is just finding its feet, but the opportunity is to understand the front line players, the actual proteins and protein complexes, that do the work of managing cellular life.
  • The report forecasts the market size out for five years for a number of different market segments.

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

Retrieved on: 
土曜日, 12月 30, 2023
Professional Services, Finance, SomaLogic, Intellectual property, Labcorp, LAB, ISS, Acquisition, Transaction, LH, Pressure, Illumina, Security (finance)

As we quickly approach the January 4th Special Meeting of Shareholders, we want to reiterate our strong opposition to the Transaction because it (i.)

Key Points: 
  • As we quickly approach the January 4th Special Meeting of Shareholders, we want to reiterate our strong opposition to the Transaction because it (i.)
  • SomaLogic continues to dodge critical questions and instead simply repeats the same tired and weak points in support of the Proposed Merger.
  • As we have comprehensively articulated , SomaLogic has exciting opportunities to create value by terminating the Proposed Merger and pursuing alternative paths.
  • The Company should immediately activate the following simple five-point plan:
    Shareholders should not accept what is clearly a flawed and value-destructive deal.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2024 – (NASDAQ: ILMN)

Retrieved on: 
木曜日, 12月 14, 2023
NEXT, Fraud, ILMN, GRAIL, Illumina, Icahn, Security (finance)

DEADLINE: January 9, 2024 Shareholders should not delay in registering for this class action.

Key Points: 
  • DEADLINE: January 9, 2024 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is January 9, 2024.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2024 – (NASDAQ: ILMN)

Retrieved on: 
月曜日, 12月 11, 2023
NEXT, Fraud, ILMN, GRAIL, Illumina, Icahn, Security (finance)

DEADLINE: January 9, 2024 Shareholders should not delay in registering for this class action.

Key Points: 
  • DEADLINE: January 9, 2024 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is January 9, 2024.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2024 – (NASDAQ: ILMN)

Retrieved on: 
木曜日, 11月 30, 2023
NEXT, Fraud, ILMN, GRAIL, Illumina, Icahn, Security (finance)

DEADLINE: January 9, 2024 Shareholders should not delay in registering for this class action.

Key Points: 
  • DEADLINE: January 9, 2024 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is January 9, 2024.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.